Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Value of Pelobreath

The value per share of Pelobreath is higher than their price target. That's exactly what I was going to I saw with, I had a big position in Twitter when Elon Musk was trying to buy it and backed out. And yours is right in line with average. There are one or two who I think we mentioned about a billion to 1.1 billion. that's about where a lot of more.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner